AbbVie to Launch Ovarian Cancer Drug ELAHERE in UK at US Price Levels

Published On 2025-09-30 09:27 GMT | Update On 2025-09-30 09:27 GMT

New Delhi: AbbVie has announced that it will launch its ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) in the United Kingdom at a list price equivalent to that in the United States, underscoring the company's strategy to ensure that developed nations recognize the value of its innovation.

ELAHERE, a first-in-class FRα-directed antibody drug conjugate (ADC), is indicated for adult patients with folate receptor-alpha positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic regimens. It is the first new treatment in a decade licensed in the UK for this category of ovarian cancer.

“Developed markets must recognize and support the value that innovative therapies bring to patients and societies to help ensure sustainable access and continued investment in medical innovation so that patients everywhere benefit from the next generation of therapies,” said Jeff Stewart, executive vice president and chief commercial officer, AbbVie.

The company confirmed it is in discussions with the National Institute for Health and Care Excellence (NICE) to secure fair value assessment for ELAHERE, which will determine its launch viability in the UK.

Also Read: AbbVie submits new drug application to USFDA for Tavapadon for Parkinsons disease

The drug, which received European Commission approval in November 2024 and full FDA approval in March 2024, was granted authorization by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) earlier in July.

Globally, AbbVie is positioning ELAHERE as a transformative therapy in oncology, supported by its broader pipeline of more than 35 investigational medicines across both blood cancers and solid tumors.

ELAHERE is an antibody-drug conjugate (ADC) that targets folate receptor alpha (FRα), a protein highly expressed in ovarian cancer cells. It combines a monoclonal antibody with a potent cytotoxic agent, DM4 (a tubulin inhibitor), to deliver targeted killing of cancer cells while limiting systemic exposure. The therapy is designed to address patients with limited treatment options and high unmet need in platinum-resistant ovarian cancer.

Also Read: AbbVie announces USD 195 million investment to expand API manufacturing in US

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Parthika Patel

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AbbVie to Launch Ovarian Cancer Drug ELAHERE in UK at US Price Levels

Similar News

Bombay HC Quashes Maharashtra FDA, CDSCO Stop-Production Orders Against 2 Pharma Firms

Indian Immunologicals Launches Raksha-IBR, India's First DIVA Vaccine Against IBR

Rajasthan Drug Official Under Probe for Misreporting Spurious Medicines

Intas Pharma Told to Narrow Margins, Extend Duration in Pembrolizumab Trial Protocol

Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure

Novartis commences tender offer to buy Tourmaline Bio

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE